| 1. |
Vallee, H. and Carré, H. (1904) Nature infectieuse de ľanemie de cheval. C. R. Acad. Sci.
139, 331–333.
|
| |
| 2. |
Coffin, J. M., Huges, S. H., and Varmus, H. E. (1997) Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY.
|
| |
| 3. |
Pereira, L. A., Bentley, K., Peeters, A., Churchill, M. J., and Deacon, N. J. (2000) A compilation of cellular transcription
factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res.
28, 663–668.
|
| |
| 4. |
Freed, E. O. (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology
251, 1–15.
|
| |
| 5. |
Li, X., Quan, Y., and Wainberg, M. A. (1997) Controlling elements in replication of the human immunodeficiency virus type
1. Cell Mol. Biol. (Noisy.-le-grand)
43, 443–454.
|
| |
| 6. |
Wyatt, R. and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science
280, 1884–1888.
|
| |
| 7. |
Kim, V. N., Mitrophanous, K., Kingsman, S. M., and Kingsman, A. J. (1998) Minimal requirement for a lentivirus vector based
on human immunodeficiency virus type 1. J. Virol.
72, 811–816.
|
| |
| 8. |
Chinnasamy, D., Chinnasamy, N., Enriquez, M. J., Otsu, M., Morgan, R. A., and Candotti, F. (2000) Lentiviral-mediated gene
transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood
96, 1309–1316.
|
| |
| 9. |
Inubushi, R. and Adachi, A. (1999) Cell-dependent function of HIV-1 Vif for virus replication (Review). Int. J. Mol. Med.
3, 473–476.
|
| |
| 10. |
Sheehy, A. M., Gaddis, N. C., Choi, J. O., and Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is
suppressed by the viral VIF protein. Nature
418, 646–650.
|
| |
| 11. |
Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997) Sustained expression of genes delivered directly
into liver and muscle by lentiviral vectors. Nat. Genet.
17, 314–317.
|
| |
| 12. |
Bukrinsky, M. and Adzhubei, A. (1999) Viral protein R of HIV-1. Rev. Med. Virol.
9, 39–49.
|
| |
| 13. |
Elder, R. T., Benko, Z., and Zhao, Y. (2002) HIV-1 VPR modulates cell cycle G2/M transition through an alternative cellular
mechanism other than the classic mitotic checkpoints. Front. Biosci.
7, d349–d357.
|
| |
| 14. |
Kappes, J. C. (1995) Viral protein x. Curr. Top. Microbiol. Immunol.
193, 121–132.
|
| |
| 15. |
Connor, R. I., Chen, B. K., Choe, S., and Landau, N. R. (1995) Vpr is required for efficient replication of human immunodeficiency
virus type-1 in mononuclear phagocytes. Virology
206, 935–944.
|
| |
| 16. |
Mahalingam, S., Ayyavoo, V., Patel, M., Kieber-Emmons, T., and Weiner, D. B. (1997) Nuclear import, virion incorporation,
and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.
J. Virol.
71, 6339–6347.
|
| |
| 17. |
Eckstein, D. A., Sherman, M. P., Penn, M. L., et al. (2001) HIV-1 Vpr enhances viral burden by facilitating infection of tissue
macrophages but not nondividing CD4+ T cells. J. Exp. Med.
194, 1407–1419.
|
| |
| 18. |
De Noronha, C. M., Sherman, M. P., Lin, H. W., et al. (2001) Dynamic disruptions in nuclear envelope architecture and integrity
induced by HIV-1 Vpr. Science
294, 1105–1108.
|
| |
| 19. |
Jowett, J. B., Xie, Y. M., and Chen, I. S. (1999) The presence of human immuno-deficiency virus type 1 Vpr correlates with
a decrease in the frequency of mutations in a plasmid shuttle vector. J. Virol.
73, 7132–7137.
|
| |
| 20. |
Mansky, L. M. (1996) The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology
222, 391–400.
|
| |
| 21. |
Marcello, A., Zoppe, M., and Giacca, M. (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.
IUBMB Life
51, 175–181.
|
| |
| 22. |
Jones, K. A. (1997) Taking a new TAK on tat transactivation. Genes Dev.
11, 2593–2599.
|
| |
| 23. |
Cujec, T. P., Cho, H., Maldonado, E., Meyer, J., Reinberg, D., and Peterlin, B. M. (1997) The human immunodeficiency virus
transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell Biol.
17, 1817–1823.
|
| |
| 24. |
Benkirane, M., Chun, R. F., Xiao, H., et al. (1998) Activation of integrated provirus requires histone acetyltransferase.
p300 and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem.
273, 24,898–24,905.
|
| |
| 25. |
Roebuck, K. A., Rabbi, M. F., and Kagnoff, M. F. (1997) HIV-1 Tat protein can transactivate a heterologous TATAA element independent
of viral promoter sequences and the transactivation response element. AIDS
11, 139–146.
|
| |
| 26. |
de Parseval, A. and Elder, J. H. (1999) Demonstration that orf2 encodes the feline immunodeficiency virus transactivating
(Tat) protein and characterization of a unique gene product with partial rev activity. J. Virol.
73, 608–617.
|
| |
| 27. |
Purcell, D. F. and Martin, M. A. (1993) Alternative splicing of human immuno-deficiency virus type 1 mRNA modulates viral
protein expression, replication, and infectivity. J. Virol.
67, 6365–6378.
|
| |
| 28. |
Pollard, V. W. and Malim, M. H. (1998) The HIV-1 Rev protein. Annu. Rev. Microbiol.
52, 491–532.
|
| |
| 29. |
Fukumori, T., Kagawa, S., Iida, S., et al. (1999) Rev-dependent expression of three species of HIV-1 mRNAs (review). Int. J. Mol. Med.
3, 297–302.
|
| |
| 30. |
Yi, R., Bogerd, H. P., and Cullen, B. R. (2002) Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic
expression of incompletely spliced human immunodeficiency virus mRNAs. J. Virol.
76, 2036–2042.
|
| |
| 31. |
Ruhl, M., Himmelspach, M., Bahr, G. M., et al. (1993) Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency
virus type 1 Rev activation domain mediating trans-activation. J. Cell Biol.
123, 1309–1320.
|
| |
| 32. |
Bogerd, H. P., Fridell, R. A., Madore, S., and Cullen, B. R. (1995) Identification of a novel cellular cofactor for the Rev/Rex
class of retroviral regulatory proteins. Cell
82, 485–494.
|
| |
| 33. |
Fritz, C. C., Zapp, M. L., and Green, M. R. (1995) A human nucleoporin-like protein that specifically interacts with HIV Rev.
Nature
376, 530–533.
|
| |
| 34. |
Reddy, T. R., Xu, W., Mau, J. K., et al. (1999) Inhibition of HIV replication by dominant negative mutants of Sam68, a functional
homolog of HIV-1 Rev. Nat. Med.
5, 635–642.
|
| |
| 35. |
Boris-Lawrie, K., Roberts, T. M., and Hull, S. (2001) Retroviral RNA elements integrate components of post-transcriptional
gene expression. Life Sci.
69, 2697–2709.
|
| |
| 36. |
Zolotukhin, A. S., Valentin, A., Pavlakis, G. N., and Felber, B. K. (1994) Continuous propagation of RRE(-) and Rev(-)RRE(-)
human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J. Virol.
68, 7944–7952.
|
| |
| 37. |
Gasmi, M., Glynn, J., Jin, M. J., Jolly, D. J., Yee, J. K., and Chen, S. T. (1999) Requirements for efficient production and
transduction of human immunodeficiency virus type 1-based vectors. J. Virol.
73, 1828–1834.
|
| |
| 38. |
Bour, S. and Strebel, K. (2000) HIV accessory proteins: multifunctional components of a complex system. Adv. Pharmacol.
48, 75–120.
|
| |
| 39. |
Geyer, M., Fackler, O. T., and Peterlin, B. M. (2001) Structure—function relationships in HIV-1 Nef. EMBO Rep.
2, 580–585.
|
| |
| 40. |
Arold, S. T. and Baur, A. S. (2001) Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this
small HIV protein. Trends Biochem. Sci.
26, 356–363.
|
| |
| 41. |
Chazal, N., Singer, G., Aiken, C., Hammarskjold, M. L., and Rekosh, D. (2001) Human immunodeficiency virus type 1 particles
pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J. Virol.
75, 4014–4018.
|
| |
| 42. |
Clapham, P. R. and McKnight, A. (2001) HIV-1 receptors and cell tropism. Br. Med. Bull.
58, 43–59.
|
| |
| 43. |
Jonckheere, H., Anne, J., and De Clercq, E. (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors.
Med. Res. Rev.
20, 129–154.
|
| |
| 44. |
Gallay, P., Hope, T., Chin, D., and Trono, D. (1997) HIV-1 infection of nondividing cells through the recognition of integrase
by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA
94, 9825–9830.
|
| |
| 45. |
Popov, S., Rexach, M., Ratner, L., Blobel, G., and Bukrinsky, M. (1998) Viral protein R regulates docking of the HIV-1 preintegration
complex to the nuclear pore complex. J. Biol. Chem.
273, 13,347–13,352.
|
| |
| 46. |
Jenkins, Y., McEntee, M., Weis, K., and Greene, W. C. (1998) Characterization of HIV-1 vpr nuclear import: analysis of signals
and pathways. J. Cell Biol.
143, 875–885.
|
| |
| 47. |
Haffar, O. K., Popov, S., Dubrovsky, L., et al. (2000) Two nuclear localization signals in the HIV-1 matrix protein regulate
nuclear import of the HIV-1 pre-integration complex. J. Mol. Biol.
299, 359–368.
|
| |
| 48. |
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., and Charneau, P. (2000) HIV-1 genome nuclear import is mediated
by a central DNA flap. Cell
101, 173–185.
|
| |
| 49. |
Katzman, M. and Katz, R. A. (1999) Substrate recognition by retroviral integrases. Adv. Virus Res.
52, 371–395.
|
| |
| 50. |
Kaplan, A. H. and Swanstrom, R. (1991) Human immunodeficiency virus type 1 gag proteins are processed in two cellular compartments.
Proc. Natl. Acad. Sci. USA
88, 4528–4532.
|
| |
| 51. |
Farson, D., Witt, R., McGuinness, R., et al. (2001) A new-generation stable inducible packaging cell line for lentiviral vectors.
Hum. Gene Ther.
12, 981–997.
|
| |
| 52. |
Xu, K., Ma, H., McCown, T. J., Verma, I. M., and Kafri, T. (2001) Generation of a stable cell line producing high-titer self-inactivating
lentiviral vectors. Mol. Ther.
3, 97–104.
|
| |
| 53. |
Seppen, J., Barry, S. C., Harder, B., and Osborne, W. R. (2001) Lentivirus administration to rat muscle provides efficient
sustained expression of erythropoietin. Blood
98, 594–596.
|
| |
| 54. |
Baek, S. C., Lin, Q., Robbins, P. B., Fan, H., and Khavari, P. A. (2001) Sustainable systemic delivery via a single injection
of lentivirus into human skin tissue. Hum. Gene Ther.
12, 1551–1558.
|
| |
| 55. |
Peng, K. W., Pham, L., Ye, H., et al. (2001) Organ distribution of gene expression after intravenous infusion of targeted
and untargeted lentiviral vectors. Gene Ther.
8, 1456–1463.
|
| |